Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have multiple myeloma that has come back or stopped responding to treatment, and whose disease got worse during or after their most recent myeloma treatment.
• People in the dose-finding part (Part 1) whose myeloma no longer responds to, who cannot tolerate, or who are not suitable for currently available standard treatments known to help with myeloma.
• People in the dose-expansion part (Part 2) whose myeloma has relapsed or stopped responding after a specific number of prior treatments — including at least one drug from each of these groups: an immunomodulatory drug, a proteasome inhibitor, an anti-CD38 antibody, and a T-cell redirecting therapy (such as CAR-T or a bispecific antibody treatment) — unless a person is not considered a suitable candidate for T-cell redirecting therapy.
• People whose myeloma can be measured through standard tests, confirming the disease is detectable.
• People who are reasonably active and able to care for themselves, as measured by a standard health performance scale (a score of 0 or 1 on the ECOG scale).
• People who agree to follow a specific pregnancy prevention plan required by the study.

Who may not be able to join:

• People whose myeloma has spread to the brain or spinal cord, or who have a history of this.
• People who have plasma cell leukaemia, Waldenström's macroglobulinaemia, POEMS syndrome, or a significant condition caused by abnormal protein deposits (light-chain amyloidosis).
• People with a serious heart condition or significantly reduced heart function.
• People who had a COVID-19 infection within 14 days before starting the study (for mild or no symptoms) or within 28 days (for severe illness).
• People in Part 1 who have previously been treated with the study drug CC-92480.
• People in Part 2 who have previously been treated with CC-92480, tazemetostat, BMS-986158, or trametinib.
• People who have ever received a donor (allogeneic) stem cell transplant, or who received their own (autologous) stem cell transplant within 12 weeks before starting the study.
• People who received any of the following within 14 days before starting the study: a plasma-filtering procedure (plasmapheresis), major surgery, radiation therapy (other than localised treatment for myeloma-related bone problems), or any systemic anti-myeloma drug treatment.
• People who took part in another clinical trial or used an experimental treatment within 28 days, or within 5 half-lives of that drug (whichever is shorter), before starting the study.
• People who received a COVID-19 vaccine within 14 days before the first day of treatment.
• Additional eligibility requirements defined in the study protocol may also apply (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.